Affiliation:
1. Russian Gerontology Research and Clinical Centre, Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Abstract
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases worldwide. It is the leading cause of dementia in both older and oldest old population. The standard treatment for AD dementia is based on two groups of drugs: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA glutamate receptor modulator memantine. At moderate and severe stages of dementia, it is often necessary to use both a cholinergic inhibitor and memantine simultaneously. This review discusses current capabilities, efficacy and safety of combined therapy for Alzheimer's. It also covers details the features of using fixed combinations of donepezil and memantine in clinical practice.
Publisher
Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology